Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus LODINE.
ANSAID vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category C
Category C
NSAID
NSAID